Loading
companiesCompany
Achieve Life Sciences (formerly OncoGenex)
Achieve Life Sciences carries the trial record of OncoGenex, whose antisense drug custirsen failed phase 3 trials in prostate and lung cancer before the company turned to a smoking-cessation medicine.
Also called: Achieve Life Sciences, Inc.OncoGenex PharmaceuticalsOncoGenex
Overview
OncoGenex Pharmaceuticals, founded in 2000 in Bothell, Washington, developed custirsen (OGX-011), an antisense inhibitor of clusterin, and led the phase 3 SYNERGY and AFFINITY trials in metastatic castration-resistant prostate cancer and a phase 3 trial in non-small cell lung cancer, none of which improved survival. In 2017 it merged with Achieve Life Sciences, which now develops cytisinicline for smoking cessation, a cancer prevention aim. The custirsen trials sit on ClinicalTrials.gov under the Achieve name.
Headquarters
Bothell, WA, US
Scorecard
All companies#473of 1244 companies, score 5
- modalities +2
- registry trials +6
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 9 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2000
Withdrawnantisense oligonucleotide
A drug designed to switch off a protein that helps cancer cells survive chemotherapy. Two large trials found it added nothing.
Similar pages
- CompanyIonis Pharmaceuticals
Shares Oligonucleotide therapeutics, Prostate cancer, Non-small-cell lung cancer.
- TermProstate cancer programmes that failed, and what each failure taught
Shares AFFINITY, SYNERGY, Oligonucleotide therapeutics, Prostate cancer.
- TrialTROPIC
Shares AFFINITY, Prostate cancer.
- TrialTAX 327
Shares SYNERGY, Prostate cancer.
- TreatmentCabazitaxel
Shares AFFINITY, Prostate cancer.
- PathwayRNA splicing
cancers
fronts
technologies
drugs
Withdrawnantisense oligonucleotide